(RTTNews) - Healthcare company Johnson & Johnson (JNJ) announced on Monday that it has agreed to acquire clinical-stage biopharmaceutical company Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
